X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

This is not a special effect: New video shows the destruction of a rogue cell

By Robert Zirkelbach  |    April 10, 2017
In the latest video of our Cells series, part of the GOBOLDLY™ campaign, we witness the destruction of a rogue cell that causes rheumatoid arthritis (RA), a disease that affects 1.3 million Americans.   Read More

RA medicines often demonstrate far greater benefits to patients than initially understood

By Lauren Neves  |    April 5, 2017
In the last decade, new therapies to treat rheumatoid arthritis (RA), a progressive and painful autoimmune disorder, have expanded patients’ treatment options and significantly improved outcomes,...   Read More

Burden on patients: Insurance benefit design’s impact on patient access to medicines

By Allyson Funk  |    June 30, 2016
Last week, we looked at access to medicines in health insurance exchanges for HIV/AIDS, oncology, cystic fibrosis, mental health and multiple sclerosis. The analysis by Avalere Health presents data...   Read More

New report celebrates a decade of progress in chronic diseases

By Holly Campbell  |    February 25, 2016
In the last 10 years, incredible progress has been made by the biopharmaceutical industry in the treatment of chronic diseases. With about half of all Americans, or 117 million people, living with...   Read More

Patient Profile: Out-of-Pocket Cost Burden for Rheumatoid Arthritis Patient

By Allyson Funk  |    April 9, 2015
Last month, we walked through how managing chronic myeloid leukemia with a health insurance exchange plan can leave patients with burdensome out-of-pocket costs and put patients’ access to medicines...   Read More

New Evidence of Discrimination in Essential Health Benefit Plans

By Tina Stow  |    January 30, 2015
While the Affordable Care Act (ACA) expanded access to health insurance coverage for millions, a new study from the Harvard T.H. Chan School of Public Health reveals that insurers may be...   Read More

Burden on Patients: Preserving the ‘New Normal’ for Patients with Rheumatoid Arthritis

By Allyson Funk  |    June 24, 2014
In the last 20 years, medical advances have transformed the lives of Rheumatoid Arthritis (RA) patients. Instead of managing symptoms, innovative medicines help slow disease progression and can even...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."